捨得酒業(600702.SH)大跌8% 第一大股東股權遭司法凍結
格隆匯11月18日丨捨得酒業(600702.SH)大跌7.96%,報29.6元,暫成交3.9億元,最新總市值100億元。從天眼查獲悉,四川沱牌捨得集團有限公司新增3條司法協助信息。其中,被執行人同為天洋控股集團有限公司,被執行股權皆為其所持有的沱牌捨得集團1.6257億股權。執行法院分別是北京市第三中級人民法院與遂寧市中級人民法院,凍結時間起始日期為本月8日或本月11日。持續時間長達1095天,即持續至2022年11月。沱牌捨得集團為捨得酒業第一大股東,持股29.85%。而天洋控股自2016年6月正式入駐沱牌捨得,參與捨得改制後,認繳出資額1.6275億元,持沱牌捨得集團70%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.